Cibus, Inc. (CBUS) Revenue History
Annual and quarterly revenue from 2015 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
CBUS's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CBUS Revenue Analysis (2015–2024)
As of March 4, 2026, Cibus, Inc. (CBUS) generated trailing twelve-month (TTM) revenue of $3.8 million, reflecting significant decline in growth of -63.1% year-over-year. The most recent quarter (Q3 2025) recorded $615,000 in revenue, down 34.1% sequentially.
Looking at the longer-term picture, CBUS's 5-year compound annual growth rate (CAGR) stands at -10.2%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $26.0 million in 2021.
Revenue diversification analysis shows CBUS's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RPRX (+3.7% YoY), LGND (+64.8% YoY), and INVA (+14.5% YoY), CBUS has underperformed the peer group in terms of revenue growth. Compare CBUS vs RPRX →
Peer Comparison
Compare CBUS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CBUSCurrent | $4M | -63.1% | -10.2% | -6062.8% | |
 RPRX | $2.4B | +3.7% | +2.3% | 65.6% | |
 LGND | $167M | +64.8% | +6.8% | -13.5% | |
 INVA | $425M | +14.5% | +4.8% | 38.5% | |
 BTX | $41M | - | - | 87.7% | |
 XOMAP | $28M | +118.0% | +9.2% | -140.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $4.3M | +134.6% | $4.3M | 100.0% | $-258,396,000 | -6062.8% |
| 2023 | $1.8M | +1057.3% | $1.4M | 78.3% | $-318,883,000 | -17550.0% |
| 2022 | $157K | -99.4% | $-1,377,000 | -877.1% | $-22,370,000 | -14248.4% |
| 2021 | $26.0M | +9.0% | $-2,570,000 | -9.9% | $-29,332,000 | -112.9% |
| 2020 | $23.9M | +226.9% | $-11,276,000 | -47.3% | $-43,832,000 | -183.8% |
| 2019 | $7.3M | +2991.5% | $-1,984,000 | -27.2% | $-39,673,000 | -543.8% |
| 2018 | $236K | -53.5% | $-845,000 | -358.1% | $-28,115,000 | -11913.1% |
| 2017 | $508K | +27.3% | $-43,000 | -8.5% | $-25,789,000 | -5076.6% |
| 2016 | $399K | -68.6% | $199K | 49.9% | $-12,109,000 | -3034.8% |
| 2015 | $1.3M | - | $521K | 41.0% | $-5,814,000 | -457.1% |
See CBUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CBUS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CBUS vs AGIO
See how CBUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CBUS's revenue growth accelerating or slowing?
CBUS revenue declined -63.1% year-over-year, contrasting with the 5-year CAGR of -10.2%. TTM revenue fell to $4M. This reverses the prior growth trend.
What is CBUS's long-term revenue growth rate?
Cibus, Inc.'s 5-year revenue CAGR of -10.2% reflects the variable expansion pattern. Current YoY growth of -63.1% is below this long-term average.
How is CBUS's revenue distributed by segment?
CBUS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2024 are available for download. Segment mix reveals concentration and diversification trends.